miR-219-5p inhibits proliferation and clonogenicity in chordoma cells and is associated with tumor recurrence

Wei,Wei; Zhang,Qiuhang; Wang,Zhenlin; Yan,Bo; Feng,Yanjun; Li,Pu

doi:10.3892/ol.2016.5222

miR-219-5p inhibits proliferation and clonogenicity in chordoma cells and is associated with tumor recurrence

Authors:
- Wei Wei
- Qiuhang Zhang
- Zhenlin Wang
- Bo Yan
- Yanjun Feng
- Pu Li
View Affiliations

Affiliations: Department of Otolaryngology, Head and Neck Surgery, Skull Base Surgery Center, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China
Published online on: October 5, 2016 https://doi.org/10.3892/ol.2016.5222
Pages: 4568-4576
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chordoma is a rare malignant bone tumor that is usually localized to the skull base, vertebral column and sacrum. The transcription factor brachyury, which is encoded by the T gene, has a critical role in the development and progression of chordoma, although the mechanisms underlying brachyury regulation remain unclear. The aim of the current study was to identify and characterize microRNAs (miRs) that regulate brachyury expression in chordoma. MicroRNAs that target brachyury were predicted using miRanda and TargetScan. Using reverse transcription‑quantitative polymerase chain reaction, miR‑219‑5p was shown to be significantly downregulated in chordoma tissues and the U‑CH2 chordoma cell lines. A dual‑luciferase reporter assay was used to validate the inhibitory effect of miR‑219‑5p on brachyury mRNA expression. The expression level of brachyury was downregulated in U‑CH2 cells following transfection with miR‑219‑5p mimics and upregulated following transfection with the miR‑219‑5p inhibitor. The effects of miR‑219‑5p on the proliferation and clonogenicity of chordoma cells were assessed using cell counting kit‑8, EdU and clone formation assays. These in vitro results indicated that miR‑219‑5p may have an important role in regulating the cell proliferation and clonogenicity of human chordoma cells, potentially by targeting brachyury. Furthermore, the associations between the expression levels of miR‑219‑5p and various clinicopathological factors were analyzed, and miR‑219‑5p expression was shown to correlate with tumor extent and recurrence. These results suggested that miR‑219‑5p functions as a tumor suppressor in chordoma and, therefore, that miR‑219‑50 may be a potential target for therapeutic intervention.

View Figures

View References

1	Casali PG, Stacchiotti S, Sangalli C, Olmi P and Gronchi A: Chordoma. Curr Opin Oncol. 19:367–370. 2007. View Article : Google Scholar : PubMed/NCBI
2	Stippler M, Gardner PA, Snyderman CH, Carrau RL, Prevedello DM and Kassam AB: Endoscopic endonasal approach for clival chordomas. Neurosurgery. 64:268–277. 2009. View Article : Google Scholar : PubMed/NCBI
3	Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, Boshoff C and Flanagan AM: Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Patho. 209:157–165. 2006. View Article : Google Scholar
4	Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM and Kelley MJ: T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet. 41:1176–1178. 2009. View Article : Google Scholar : PubMed/NCBI
5	Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, et al: Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: A genetic and functional-based study. J Pathol. 223:327–335. 2011. View Article : Google Scholar : PubMed/NCBI
6	Hsu W, Mohyeldin A, Shah SR, ap Rhys CM, Johnson LF, Sedora-Roman NI, Kosztowski TA, Awad OA, McCarthy EF, Loeb DM, et al: Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J Neurosurg. 115:760–769. 2011. View Article : Google Scholar : PubMed/NCBI
7	Szuhai K and Hogendoorn PC: ‘The chicken or the egg?’ dilemma strikes back for the controlling mechanism in chordoma(#). J Pathol. 228:261–265. 2012. View Article : Google Scholar : PubMed/NCBI
8	Farazi TA, Spitzer JI, Morozov P and Tuschl T: MiRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
9	Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med. 17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
10	Le XF, Merchant O, Bast RC and Calin GA: The roles of microRNAs in the cancer nvasion-metastasis cascade. Cancer Microenviron. 3:137–147. 2010. View Article : Google Scholar : PubMed/NCBI
11	Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, Li D and Zhou Y: The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol. 45:197–208. 2014.PubMed/NCBI
12	Xu XM, Qian JC, Deng ZL, Cai Z, Tang T, Wang P, Zhang KH and Cai JP: Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett. 4:339–345. 2012.PubMed/NCBI
13	Jikuzono T, Kawamoto M, Yoshitake H, Kikuchi K, Akasu H, Ishikawa H, Hirokawa M, Miyauchi A, Tsuchiya S, Shimizu K and Takizawa T: The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int J Oncol. 42:1858–1868. 2013.PubMed/NCBI
14	Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam FW and Nkenke E: MiR-186, miR-3651 and miR-494: Potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 31:1429–1436. 2014.PubMed/NCBI
15	Flanagan AM and Yamaguchi T: ChordomaWHO Classification of Tumours of Soft Tissue and Bone. IARC Press; Lyon: pp. 328–329. 2013
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Duan Z, Choy E, Nielsen GP, Rosenberg A, Iafrate J, Yang C, Schwab J, Mankin H, Xavier R and Hornicek FJ: Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res. 28:746–752. 2010.PubMed/NCBI
18	Osaka E, Yang X, Shen JK, Yang P, Feng Y, Mankin HJ, Hornicek FJ and Duan Z: MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. J Orthop Res. 32:1075–1082. 2014. View Article : Google Scholar : PubMed/NCBI
19	Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, et al: Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. J Orthop Res. 32:695–701. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Schiff D, Park D and Abounader R: MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS One. 12:e915462014. View Article : Google Scholar
21	Long C, Jiang L, Wei F, Ma C, Zhou H, Yang S, Liu X and Liu Z: Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS One. 8:e666762013. View Article : Google Scholar : PubMed/NCBI
22	Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern CD, et al: An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J Pathol. 228:274–285. 2012. View Article : Google Scholar : PubMed/NCBI
23	Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco R, Diss TC and Flanagan AM: Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod Pathol. 22:996–1005. 2009. View Article : Google Scholar : PubMed/NCBI
24	Pillay N, Amary FM, Berisha F, Tirabosco R and Flanagan AM: P63 does not regulate brachyury expression in human chordomas and osteosarcomas. Histopathology. 59:1025–1072. 2011. View Article : Google Scholar : PubMed/NCBI
25	Rao SA, Santosh V and Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol. 23:1404–1417. 2010. View Article : Google Scholar : PubMed/NCBI
26	Rao SA, Arimappamagan A, Pandey P, Santosh V, Hegde AS, Chandramouli BA and Somasundaram K: MiR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS One. 8:e631642013. View Article : Google Scholar : PubMed/NCBI
27	Zhi F, Zhou G, Wang S, Shi Y, Peng Y, Shao N, Guan W, Qu H, Zhang Y, Wang Q, et al: A microRNA expression signature predicts meningioma recurrence. Int J Cancer. 132:128–136. 2013. View Article : Google Scholar : PubMed/NCBI
28	Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, Lv C, Zheng D and Luo R: MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 23:884–891. 2012. View Article : Google Scholar
29	Huang C, Cai Z, Huang M, Mao C, Zhang Q, Lin Y, Zhang X, Tang B, Chen Y, Wang X, et al: MiR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α. J Clin Endocrinol Metab. 100:E204–E213. 2015. View Article : Google Scholar : PubMed/NCBI
30	Kitamura Y, Sasaki H, Kimura T, Miwa T, Takahashi S, Kawase T and Yoshida K: Molecular and clinical risk factors for recurrence of skull base chordomas: Gain on chromosome 2p, expression of brachyury and lack of irradiation negatively correlate with patient prognosis. J Neuropathol Exp Neurol. 72:816–823. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zhang L, Guo S, Schwab JH, Nielsen GP, Choy E, Ye S, Zhang Z, Mankin H, Hornicek FJ, Duan Z, et al: Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma. PLoS One. 8:e758512013. View Article : Google Scholar : PubMed/NCBI